Javier San Martin M.D.
Net Worth
Last updated:
What is Javier San Martin M.D. net worth?
The estimated net worth of Dr. Javier San Martin M.D. is at least $11,449,627 as of 5 Jan 2024. He owns shares worth $3,932,226 as insider, has earned $4,149,551 from insider trading and has received compensation worth at least $3,367,850 in Arrowhead Pharmaceuticals, Inc..
What is the salary of Javier San Martin M.D.?
Dr. Javier San Martin M.D. salary is $673,570 per year as Chief Medical Officer in Arrowhead Pharmaceuticals, Inc..
How old is Javier San Martin M.D.?
Dr. Javier San Martin M.D. is 60 years old, born in 1965.
What stocks does Javier San Martin M.D. currently own?
As insider, Dr. Javier San Martin M.D. owns shares in one company:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Arrowhead Pharmaceuticals, Inc. (ARWR) | Chief Medical Officer | 198,497 | $19.81 | $3,932,226 |
What does Arrowhead Pharmaceuticals, Inc. do?
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in Phase 2b clinical trial to reduce production of angiopoietin-like protein 3; ARO-HSD, which is in Phase 1/2a clinical trial to treat liver diseases; ARO-ENaC, which is in a Phase 1/2a clinical trial to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; ARO-C3 for the treatment of complement-mediated disease that is in Phase 1/2a clinical trial; ARO-Lung2 for the treatment of chronic obstructive pulmonary disorder; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-XDH to treat uncontrolled gout; ARO-COV for the treatment of COVID-19 and other pulmonary-borne pathogens; and ARO-HIF2, which is in phase 1b clinical trial to treat clear cell renal cell carcinoma. It is also involved in the development of JNJ-3989, a subcutaneously administered RNAi therapeutic candidate to treat chronic hepatitis B virus infection; Olpasiran to reduce the production of apolipoprotein A; and ARO-AMG1 for treating genetically validated cardiovascular targets. Arrowhead Pharmaceuticals, Inc. has a license and research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop ARO-JNJ1, ARO-JNJ2, and ARO-JNJ3 RNAi therapeutics for liver-expressed targets; and license and research collaboration agreement with Takeda Pharmaceuticals U.S.A., Inc. to develop RNAi therapeutic candidate as a treatment for liver disease. Arrowhead Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Pasadena, California.
Javier San Martin M.D. insider trading
Arrowhead Pharmaceuticals, Inc.
Dr. Javier San Martin M.D. has made 11 insider trades between 2020-2024, according to the Form 4 filled with the SEC. Most recently he sold 800 units of ARWR stock worth $27,288 on 5 Jan 2024.
The largest trade he's ever made was exercising 19,500 units of ARWR stock on 19 Nov 2020. As of 5 Jan 2024 he still owns at least 198,497 units of ARWR stock.
Arrowhead Pharmaceuticals key executives
Arrowhead Pharmaceuticals, Inc. executives and other stock owners filed with the SEC:
- Dr. Christopher R. Anzalone (56) Chief Executive Officer, Pres & Director
- Dr. Javier San Martin M.D. (60) Chief Medical Officer
- Mr. Kenneth A. Myszkowski (59) Chief Financial Officer